Abstract： Objective： To analyze the mechanism of Jieshi Decoction in treating gouty arthritis（GA） using network pharmacology and molecular docking. Methods： Active components and targets of Jieshi Decoction were retrieved from TCMSP and BATMAN-TCM databases. GA-related targets were collected from GeneCards，CTD，and OMIM databases. Venny platform identified overlapping targets. STRING database constructed a protein-protein interaction（PPI） network. GO and KEGG enrichment analyses were performed using R software， with molecular docking validation via AutoDock Vina. Results： A total of 59 active components and 295 overlapping targets were identified. Core components included quercetin，styrene，cinnamic acid，ethylcinnamate，trans-cinnamic acid，and anethole. PPI analysis revealed AKT1，INS，TNF，IL6，TP53，and ALB as key targets. GO enrichment highlighted biological processes including response to xenobiotic stimulus and response to nutrient levels. KEGG analysis identified 197 signaling pathways，predominantly enriched in the IL-17 and AGE-RAGE signaling pathways. Molecular docking confirmed strong binding affinity between core components （quercetin， styrene） and key targets （TNF， INS）. Conclusion： Jieshi Decoction exerts anti-inflammatory， metabolic regulatory， and microenvironment- modulating effects against GA by regulating targets like AKT1 and TNF through active components like quercetin and styrene， primarily via IL-17 and AGE-RAGE signaling pathways.